DE60026584D1 - Microbielles wirkstoffabgabesystem - Google Patents

Microbielles wirkstoffabgabesystem

Info

Publication number
DE60026584D1
DE60026584D1 DE60026584T DE60026584T DE60026584D1 DE 60026584 D1 DE60026584 D1 DE 60026584D1 DE 60026584 T DE60026584 T DE 60026584T DE 60026584 T DE60026584 T DE 60026584T DE 60026584 D1 DE60026584 D1 DE 60026584D1
Authority
DE
Germany
Prior art keywords
proteins
allergic
allergens
subjects
microorganisms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60026584T
Other languages
English (en)
Other versions
DE60026584T2 (de
Inventor
Michael Caplan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allertein Therapeutics Fairfield Conn Us LLC
Original Assignee
Seer Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seer Pharmaceuticals LLC filed Critical Seer Pharmaceuticals LLC
Application granted granted Critical
Publication of DE60026584D1 publication Critical patent/DE60026584D1/de
Publication of DE60026584T2 publication Critical patent/DE60026584T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60026584T 2000-04-06 2000-12-06 Microbielles wirkstoffabgabesystem Expired - Lifetime DE60026584T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19503500P 2000-04-06 2000-04-06
US195035P 2000-04-06
US09/731,375 US8153414B2 (en) 2000-04-06 2000-12-06 Microbial delivery system
PCT/US2000/033121 WO2001066136A2 (en) 2000-04-06 2000-12-06 Microbial delivery system
US731375 2000-12-06

Publications (2)

Publication Number Publication Date
DE60026584D1 true DE60026584D1 (de) 2006-05-04
DE60026584T2 DE60026584T2 (de) 2007-03-08

Family

ID=26890647

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60026584T Expired - Lifetime DE60026584T2 (de) 2000-04-06 2000-12-06 Microbielles wirkstoffabgabesystem

Country Status (11)

Country Link
US (6) US8153414B2 (de)
EP (1) EP1272213B1 (de)
JP (3) JP2004527450A (de)
AT (1) ATE319475T1 (de)
AU (2) AU2001219510B2 (de)
CA (1) CA2403292C (de)
CY (1) CY1105216T1 (de)
DE (1) DE60026584T2 (de)
DK (1) DK1272213T3 (de)
ES (1) ES2260078T3 (de)
WO (1) WO2001066136A2 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6698162B2 (en) * 2000-03-23 2004-03-02 Teikoku Pharma Usa, Inc. Methods of producing a terminally sterilized topical patch preparation
US8246945B2 (en) * 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
DK1272213T3 (da) * 2000-04-06 2006-07-10 Seer Pharmaceuticals Llc Mikrobielt afgivelsessystem
CA2405424A1 (en) * 2000-04-07 2001-10-18 The Regents Of The University Of California Synergistic improvements to polynucleotide vaccines
US7083787B2 (en) * 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
US7060687B2 (en) * 2001-02-07 2006-06-13 Genmont Biotechnology Co. Live vaccines for allergy treatment
CN104147597A (zh) * 2002-12-16 2014-11-19 全球免疫股份有限公司 用于免疫治疗的基于酵母的疫苗
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
US20070231796A1 (en) * 2003-09-17 2007-10-04 The Regents Of The University Of California Sensor and method for detection of a target substance
JP5234445B2 (ja) * 2004-10-05 2013-07-10 源一郎 杣 薬剤
WO2006044923A2 (en) * 2004-10-18 2006-04-27 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis c infection
EP1906997A2 (de) * 2005-07-11 2008-04-09 Globeimmune, Inc. Zusammensetzungen und verfahren zur auslösung einer immunantwort auf escape-mutanten von gezielten therapien
US20070172503A1 (en) 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
TW200806789A (en) * 2006-03-27 2008-02-01 Globeimmune Inc RAS mutation and compositions and methods related thereto
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
BRPI0807828B8 (pt) * 2007-02-02 2021-05-25 Globeimmune Inc composição compreendendo leveduras e usos das mesmas, bem como método para o crescimento de leveduras e kit para o cultivo de leveduras
EP2134358A1 (de) * 2007-03-19 2009-12-23 Globeimmune, Inc. Zusammensetzungen und verfahren zur gezielten ablation von escape-mutationen bei gezielten krebstherapien
LT2244734T (lt) 2008-02-01 2016-09-12 Murdoch Childrens Research Institute Alergeno toleravimo paskatinimo būdas
EP2331125A4 (de) 2008-09-19 2013-03-27 Globeimmune Inc Immuntherapie zur für chronische hepatitis-c-virus-infektionen
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
CA2759013C (en) 2009-04-17 2021-10-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy compositions against cancer and methods
CN102639702A (zh) * 2009-07-13 2012-08-15 疫苗基因集团 使用可食用的微生物制造及施用的口服疫苗
CA2774326C (en) 2009-09-14 2023-11-07 Donald Bellgrau Modulation of yeast-based immunotherapy products and responses
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
EP2651439B1 (de) 2010-12-17 2018-09-19 Globeimmune, Inc. Zusammensetzungen und verfahren zur behandlung oder vorbeugung von menschlicher adenovirus-36-infektion
CA2827150C (en) 2011-02-12 2018-09-11 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis b infection
RU2619850C2 (ru) 2011-03-17 2017-05-18 Глоубиммьюн, Инк. Иммунотерапевтические композиции на основе дрожжей с brachyury
SG195383A1 (en) 2011-06-14 2013-12-30 Globeimmune Inc Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection
CA2844500C (en) 2011-08-17 2022-05-10 Globeimmune, Inc. Yeast-muc1 immunotherapeutic compositions and uses thereof
US20130216589A1 (en) * 2012-02-17 2013-08-22 Rich Content Biotech INC. Oral vaccine for aquatic animals
EP2841098A4 (de) 2012-04-23 2016-03-02 Allertein Therapeutics Llc Nanopartikel zur behandlung von allergien
EP2864792A1 (de) 2012-06-26 2015-04-29 Biodesix, Inc. Massenspektrumsverfahren zur auswahl und zum ausschluss von krebspatienten für eine behandlung mit immunantworterzeugenden therapien
WO2014049604A2 (en) * 2012-09-05 2014-04-03 Amrita Therapeutics Limited A novel biomedical device for cancer therapy
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
HUE051831T2 (hu) 2013-03-14 2021-03-29 Aimmune Therapeutics Inc Szájon át történõ deszenzitizálásra szolgáló földimogyoró-készítmények elõállítása
US10507235B2 (en) 2013-03-19 2019-12-17 Globeimmune, Inc. Yeast-based immunotherapy for Chordoma
WO2014160747A2 (en) 2013-03-26 2014-10-02 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
CA2907915C (en) 2013-04-03 2023-03-07 Allertein Therapeutics, Llc Immunomodulatory nanoparticle compositions comprising a plurality of nanoparticles comprising biodegradable or biocompatible polymers and hydrophilic and hydrophobic cellular components
US10226522B2 (en) 2013-08-30 2019-03-12 Globeimmune, Inc. Compositions and methods for the treatment or prevention of tuberculosis
US11215615B2 (en) 2014-04-03 2022-01-04 AllerGenis LLC Peptides, reagents and methods for detecting food allergy
EP3129036B1 (de) 2014-04-11 2021-08-11 Globeimmune, Inc. Hefebasierte immuntherapie und typ-i-interferon-empfindlichkeit
WO2017023840A1 (en) 2015-08-03 2017-02-09 Globeimmune, Inc. Modified yeast-brachyury immunotherapeutic compositions
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11547662B2 (en) 2017-10-25 2023-01-10 Allero Therapeutics B.V. Treatment of immune diseases by administration of antigen-specific formulations
AU2018358125A1 (en) 2017-11-02 2020-05-14 Societe Des Produits Nestle S.A. Methods of oral immunotherapy
CN113966229A (zh) 2019-05-10 2022-01-21 爱沐疗法公司 用于改善花生过敏患者的生活质量的方法
WO2021158857A1 (en) * 2020-02-06 2021-08-12 AllerGenis LLC Assays for detecting peanut allergies

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US588799A (en) * 1897-08-24 Mechanism
US3097141A (en) 1959-02-26 1963-07-09 Kidwell Elizabeth N Wilcox Immunological method
SE337223B (de) 1967-05-23 1971-08-02 Pharmacia Ab
US3720760A (en) 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
US4171299A (en) 1975-04-04 1979-10-16 The Regents Of The University Of California Polypeptide agents for blocking the human allergic response
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4469677A (en) 1980-02-19 1984-09-04 Michael J Gabriel Polypeptide active immunosuppressant fraction
US4338297A (en) 1980-02-19 1982-07-06 Michael Jacob G Polypeptide active pollen immunosuppressant fraction
AR231590A1 (es) 1981-04-29 1984-12-28 Ciba Geigy Ag Dispositivo de analisis inmunologico y procedimiento para obtenerlo
US4888170A (en) * 1981-10-22 1989-12-19 Research Corporation Vaccines obtained from antigenic gene products of recombinant genes
CA1338705C (en) 1981-10-22 1996-11-12 Roy Curtiss Iii Vaccines obtained from antigenic gene products of recombinant genes
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
SE8205908D0 (sv) 1982-10-18 1982-10-18 Pharmacia Diagnostics Ab Sett att bilda polymerskikt
US4849337A (en) 1983-01-31 1989-07-18 Minnesota Mining And Manufacturing Company Assaying allergen specific IgE levels with fluorogenic enzyme labeled antibody
CA1260828A (en) 1983-07-04 1989-09-26 Masakazu Iwai Therapeutic and prophylactic agent for gastrointestinal ulcers
US4579840A (en) 1983-08-12 1986-04-01 Immunetech Pharmaceuticals Method of blocking immune complex binding to immunoglobulin Fc receptors
US4816449A (en) 1984-08-09 1989-03-28 Immunetech Pharmaceuticals Immunotherapeutic anti-inflammatory peptide agents
US4680174A (en) 1984-05-24 1987-07-14 Damon Biotech, Inc. Induction of immune response by immunization with encapsulated antigen-producing cells
US4696915A (en) 1984-05-25 1987-09-29 Hoffmann-La Roche Inc. Parathymosin alpha
US5026545A (en) 1984-09-17 1991-06-25 Baxter International, Inc. Treatment of allergy and composition therefor
US4658022A (en) 1985-08-08 1987-04-14 Molecular Diagnostics, Inc. Binding of antibody reagents to denatured protein analytes
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4900556A (en) 1985-04-26 1990-02-13 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
IL86583A0 (en) 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5843710A (en) 1987-07-07 1998-12-01 Biotech Australia Pty. Limited And Csiro Vaccines against animal parasitic nematodes
US5049390A (en) 1987-09-02 1991-09-17 Allergy Immuno Technologies, Inc. Liposome containing immunotherapy agents for treating IgE mediated allergies
US5449760A (en) 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5169933A (en) 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
AT393137B (de) 1988-10-14 1991-08-26 Biomay Biotech Prod Verfahren zum screenen einer expressions-cdna- klonbank zur auffindung von polynukleotiden
US5061790A (en) 1989-07-10 1991-10-29 Molecular Diagnostics, Inc. Oxidative denaturation of protein analytes
JP2787162B2 (ja) 1989-08-24 1998-08-13 フマキラー株式会社 精製ダニアレルゲン
US5834246A (en) * 1989-09-18 1998-11-10 Vitec Aktiebolag Recombinant systems for expression of cholera B-subunit with the aid of foreign promoters and/or leader peptides
US5328991A (en) 1989-11-03 1994-07-12 Immulogic Pharmaceutical Corp. Preparation of alkali-modified cat dander allergen (Fel d I) for immunotherapeutic purposes
JP3251012B2 (ja) 1989-11-03 2002-01-28 イミユロジク・フアーマシユーチカル・コーポレーシヨン 室内塵から単離したヒトｔ細胞反応性猫蛋白質（ｔｒｆｐ）及びその利用
US5547669A (en) 1989-11-03 1996-08-20 Immulogic Pharma Corp Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I
US6019972A (en) 1989-11-03 2000-02-01 Immulogic Pharmaceutical Corporation Peptides of human T cell reactive feline protein (TRFP)
US5747641A (en) 1989-12-21 1998-05-05 Biogen Inc Tat-derived transport polypeptide conjugates
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
EP0514458A1 (de) 1990-01-31 1992-11-25 The Board of Regents for the University of Oklahoma Untersuchungsverfahren und behandlungen für autoimmunerkrankungen
US6897287B1 (en) 1990-01-31 2005-05-24 Oklahoma Medical Research Foundation Ro/SSA peptide reagents for diagnosis of autoantibodies
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5091318A (en) 1990-04-13 1992-02-25 Abbott Laboratories Binding of allergens to a solid phase
US5888762A (en) 1990-06-05 1999-03-30 Centre National De La Recherche Scientifique (Cnrs) Neurotropic growth factors comprising a homeobox peptide
EP0495052A1 (de) 1990-08-08 1992-07-22 Biomay Biotechnik Produktions- Und Handelsgesellschaft M.B.H. Allergene des erlenblütenstaubs und deren anwendungen
AU659609B2 (en) 1990-08-13 1995-05-25 Biomay Biotechnik Produktions- Und Handelsgesellschaft M.B.H. Birch pollen allergen P14 for diagnosis and therapy of allergic diseases
AT401180B (de) 1990-08-13 1996-07-25 Biomay Biotech Prod Für das baumpollenallergen p14 codierende rekombinante dna-moleküle, daraus hergestellte und abgeleitete polypeptide und deren verwendung
JP3139777B2 (ja) 1990-08-27 2001-03-05 フマキラー株式会社 組換えダニアレルゲン
ES2129410T3 (es) 1990-09-17 1999-06-16 Mitsui Chemicals Inc Policarbonato, utilizacion, produccion y purificacion de este compuesto.
US5599537A (en) 1990-12-18 1997-02-04 The General Hospital Corporation Salmonella virulence genes
US5219990A (en) 1991-01-28 1993-06-15 Biogen, Inc. Papillomavirus e2 trans-activation repressors
US5350835A (en) 1991-11-05 1994-09-27 Board Of Regents, University Of Texas Cellular nucleic acid binding protein and uses thereof in regulating gene expression and in the treatment of aids
JP3156237B2 (ja) 1991-12-24 2001-04-16 雪印乳業株式会社 抗ヒトＩｇＥ モノクローナル抗体
GB2278358B (en) * 1992-02-27 1995-07-26 Lynxvale Ltd Heterologous gene expression in Lactococcus,and the expression products therefrom
US5480972A (en) 1992-10-30 1996-01-02 The University Of Melbourne Allergenic proteins from Johnson grass pollen
DK0603992T4 (da) 1992-12-22 2001-03-05 Univ Cincinnati Oral indgivelse af immunologisk aktive biomolekyler og andre terapeutiske proteiner
US5558869A (en) 1992-12-30 1996-09-24 University Of Arkansas Major peanut allergen ara h II
AU5957694A (en) 1992-12-31 1994-08-15 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from dog dander and uses therefor
ES2114184T3 (es) 1993-02-12 1998-05-16 Mayo Foundation Composicion a base de microparticulas en fase condensada y procedimiento.
AU683454B2 (en) 1993-02-22 1997-11-13 General Hospital Corporation, The Heterologous antigens in live cell vaccine strains
JP3451572B2 (ja) 1993-03-04 2003-09-29 アサヒビール株式会社 改変したダニ主要アレルゲン及びその製造方法
WO1994021675A2 (en) 1993-03-12 1994-09-29 Immulogic Pharmaceutical Corporation T cell epitopes of ryegrass pollen allergen
US5710126A (en) 1993-03-12 1998-01-20 Immulogic Pharmaceutical Corporation T cell epitopes of ryegrass pollen allergen
US6849427B1 (en) 1993-03-12 2005-02-01 Immulogic Pharmaceutical Corp. Nucleic acids encoding a house dust mite allergen, Der p VII, and uses therefor
US5830463A (en) * 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
JP3350794B2 (ja) 1993-09-29 2002-11-25 アサヒビール株式会社 改変したダニ主要アレルゲン
JP2828391B2 (ja) 1993-10-29 1998-11-25 東燃株式会社 オリゴ糖を表面に有するリポソーム
US5449669A (en) 1993-11-10 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services IgE-binding epitopes of a major heat-stable crustacean allergen derived from shrimp
US5731157A (en) 1993-12-30 1998-03-24 The Procter And Gamble Company Two-site allergen immunoassay
US5820862A (en) 1994-04-14 1998-10-13 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
JPH07285875A (ja) 1994-04-19 1995-10-31 Mineo Hayazaki ノミアレルゲンの製造方法および該方法により製造されるノミアレルゲン
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
SE9402089D0 (sv) 1994-06-14 1994-06-14 Rudolf Valenta Recombinant allergen, fragments thereof, corresponding recombinant DNA molecules, vectors and hosts containing the DNA molecules, diagnostic and therapeutic uses of said allergens and fragments
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO1996030539A1 (fr) * 1995-03-28 1996-10-03 Asahi Breweries, Ltd. Allergene d'acarien obtenu grace au genie genetique et son procede de fabrication
US5773003A (en) 1995-03-31 1998-06-30 Immulogic, Inc. Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US6902743B1 (en) * 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US5820880A (en) 1995-06-07 1998-10-13 The United States Of America As Represented By The Secretary Of The Army Liposomal formulation
US5869040A (en) 1995-06-07 1999-02-09 Biogen, Inc Gene therapy methods and compositions
WO1997024139A1 (en) * 1995-12-29 1997-07-10 University Of Arkansas Peanut allergens and methods
US20030202980A1 (en) * 1995-12-29 2003-10-30 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
US5955593A (en) 1996-09-09 1999-09-21 Washington University BH3 interacting domain death agonist
SE9604815D0 (sv) * 1996-12-20 1996-12-20 Pharmacia & Upjohn Ab A metod of diagnosis
EP0973881A2 (de) * 1997-03-28 2000-01-26 Cytoclonal Pharmaceutics Inc. Impfstoffe aus rekombinanten mycobakterien
US5989814A (en) 1997-04-01 1999-11-23 Reagents Of The University Of California Screening methods in eucaryotic cells
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
EP0877033B1 (de) 1997-05-08 2007-09-12 Amarnath Maitra Verfahren zur Herstellung von hochmonodispersierten Polymeren hydrophiler Nanopartikel
DE19729327C1 (de) * 1997-07-09 1998-10-29 Wieland Electric Gmbh Schutzleiterklemme
US5891432A (en) 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
US6024961A (en) * 1997-11-14 2000-02-15 Washington University Recombinant avirulent immunogenic S typhi having rpos positive phenotype
AU743647B2 (en) * 1998-01-31 2002-01-31 Mt. Sinai School Of Medicine Of New York University Methods and reagents for decreasing allergic reactions
ES2284247T3 (es) 1998-04-03 2007-11-01 University Of Iowa Research Foundation Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos.
US6270723B1 (en) 1998-06-15 2001-08-07 Bbi Bioseq, Inc. Rapid cryobaric sterilization and vaccine preparation
WO1999066947A1 (en) * 1998-06-23 1999-12-29 The Board Of Trustees Of The Leland Stanford Junior University Adjuvant therapy
US6004815A (en) * 1998-08-13 1999-12-21 The Regents Of The University Of California Bacteria expressing nonsecreted cytolysin as intracellular microbial delivery vehicles to eukaryotic cells
JP2000210050A (ja) 1998-11-20 2000-08-02 Asama Kasei Kk 免疫調節活性分解物およびその製造方法並びにそれを用いた食品
AU3760100A (en) * 1999-03-16 2000-10-04 Panacea Pharmaceuticals, Llc Immunostimulatory nucleic acids and antigens
DK1272213T3 (da) * 2000-04-06 2006-07-10 Seer Pharmaceuticals Llc Mikrobielt afgivelsessystem
US8246945B2 (en) * 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
US20050063994A1 (en) * 2000-04-06 2005-03-24 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
ATE347376T1 (de) 2000-12-28 2006-12-15 Biomay Prod & Handel Behandlung von allergien
US7265208B2 (en) 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
US20050175630A1 (en) * 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof

Also Published As

Publication number Publication date
AU1951001A (en) 2001-09-17
US20130142817A1 (en) 2013-06-06
CA2403292A1 (en) 2001-09-13
US20030035810A1 (en) 2003-02-20
JP2012207032A (ja) 2012-10-25
US20110027298A1 (en) 2011-02-03
WO2001066136A2 (en) 2001-09-13
ES2260078T3 (es) 2006-11-01
CY1105216T1 (el) 2010-03-03
JP2009242427A (ja) 2009-10-22
US20040234548A1 (en) 2004-11-25
US20040208894A1 (en) 2004-10-21
EP1272213A2 (de) 2003-01-08
JP2004527450A (ja) 2004-09-09
US8153414B2 (en) 2012-04-10
CA2403292C (en) 2011-02-08
DE60026584T2 (de) 2007-03-08
EP1272213B1 (de) 2006-03-08
AU2001219510B2 (en) 2007-06-14
US20130243814A1 (en) 2013-09-19
ATE319475T1 (de) 2006-03-15
DK1272213T3 (da) 2006-07-10
WO2001066136A3 (en) 2001-12-27
US8815251B2 (en) 2014-08-26

Similar Documents

Publication Publication Date Title
DE60026584D1 (de) Microbielles wirkstoffabgabesystem
WO2001090129A3 (en) Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-base compounds
CY1110727T1 (el) Παρασκευασματα θετικων κατα gram βακτηριων για τη θεραπεια ασθενειων που περιλαμβανουν μια ανοσολογικη δυσρυθμιση
ATE517907T1 (de) 1-kestose zur behandlung von allergie und atopischer dermatitis
WO2004087203A3 (en) Immunostimulatory nucleic acid oil-in-water formulations for topical application
EP2392345A3 (de) Haptenträgerkonjugate mit virusähnlichen Partikeln und Verwendungen davon
WO2003099195A3 (en) Immunomodulatory compounds and methods of use thereof
DE60232660D1 (de) Humane dr4-antikörper und deren anwendungen
WO2003061578A3 (en) Compositions for treatment or prevention of bioterrorism
WO2002083879A3 (en) Immunotherapy based on dendritic cells
EP2065052A3 (de) Anti-IgE Vakzine
WO2004076481A3 (en) Hypoallergenic der p 1 and der p 3 proteins from dermatographoides pteronyssinus
EP2174665A3 (de) Zusammensetzungen und Verfahren für das Aktivieren der angeborenen und allergischen Immunität
Kim et al. Infection, allergy and the hygiene hypothesis: historical perspective
Pichler et al. The fold variant BM4 is beneficial in a therapeutic Bet v 1 mouse model
ATE290081T1 (de) Parietaria judaica ns-ltp-antigenvarianten, entsprechende pharmazeutische zusammensetzungen und ihre verwendung
EP1262491A3 (de) Nicht-anaphylaktogene IgE Impfstoffe
US20110020283A1 (en) Probiotic, gram-positive bacteria for the prophylaxis, suppression, or elimination of allergic reactions in humans
WO2004045556A3 (en) Methods for inhibiting allergic inflammation and other responses initiated by pollens, molds, and other non-animal derived allergens
JPH06234647A (ja) ＩｇＡ産生促進剤およびその製造法
WO2003063768A3 (en) Compositions and methods directed to anthrax toxin
WO2006081372A3 (en) Use of parasitic biological agents for prevention and control of allergic and other ige-mediated disorders
MXPA05005669A (es) Composiciones que contienen anticuerpos humanos para el tratamiento de infecciones por micobacterias.
DEARBORN BIOLOGY OF FUNGI
Danaher Advancing your practice: Complementary constituents for the management of allergic rhinitis

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: ALLERTEIN THERAPEUTICS,LLC,, FAIRFIELD, CONN., US

8364 No opposition during term of opposition